8-K: Syndax Pharmaceuticals Reports Positive Q4 and Full Year 2024 Results, Driven by Revuforj Launch

Syndax Pharmaceuticals announces its Q4 and full year 2024 financial results, highlighting the successful launch of Revuforj and providing a business update.

Summary

• Syndax Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Revuforj generated $7.7 million in net product revenue during its initial five weeks on the market.
• The company expects to submit a supplemental NDA filing for revumenib in R/R mNPM1 AML in the second quarter of 2025.
• Syndax launched Niktimvo in the U.S. in late January 2025, in partnership with Incyte.
• As of December 31, 2024, Syndax had $692.4 million in cash, cash equivalents, and investments.
• The company expects research and development expenses to be $65 to $70 million for the first quarter of 2025.
• For the full year 2025, research and development expenses are projected to be $260 to $280 million.
• Total research and development plus selling, general, and administrative expenses are expected to be $415 to $435 million for 2025.
• Syndax anticipates reaching profitability based on its cash reserves, product revenue, and interest income.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the successful launch of Revuforj, a strong cash position, and anticipated milestones. While there are increased expenses and a net loss, the overall tone is optimistic due to the commercial progress and future growth potential.

Positives

• Successful launch of Revuforj with $7.7 million in net product revenue in the initial five weeks.
• Positive pivotal data from the AUGMENT-101 trial supports sNDA filing for revumenib in R/R mNPM1 AML.
• Launch of Niktimvo in the U.S. expands Syndax's commercial portfolio.
• Strong cash position of $692.4 million provides a runway to profitability.
• Royalty Pharma agreement provides $350 million in funding based on Niktimvo sales.

Negatives

• Net loss attributable to common stockholders was $318.8 million, or $3.72 per share, for the year ended December 31, 2024, compared to a net loss of $209.4 million in 2023.
• Increased research and development expenses and selling, general, and administrative expenses contributed to the higher net loss.

Risks

• Unexpected safety or efficacy data from clinical trials could impact product development.
• Lower than expected clinical trial site activation or enrollment rates could delay timelines.
• Changes in the competitive or regulatory environment could affect commercial success.
• Failure of collaborators to support or advance collaborations or product candidates could hinder progress.
• Unexpected litigation or other disputes could negatively impact the company.

Future Outlook

Syndax expects its cash, cash equivalents, and investments, combined with anticipated product revenue and interest income, will enable the company to reach profitability. The company is not providing revenue guidance at this time.

Management Comments

• We are off to a strong start with the U.S. launch of Revuforj and are very encouraged by the early patient demand, breadth of prescribing, and coverage from payers, said Michael A. Metzger, Chief Executive Officer.
• Our early results are consistent with the high unmet need in R/R KMT2A-rearranged acute leukemia and reflect strong execution across our entire organization.
• With two first-in-class medicines on the market that address major unmet needs and a robust development strategy underway for expansion, Syndax is well-positioned to unlock the multi-billion-dollar potential of both medicines.

Industry Context

Syndax's focus on developing therapies for relapsed or refractory leukemias and GVHD addresses significant unmet needs in the oncology and hematology space. The successful launch of Revuforj positions the company as a key player in the treatment of KMT2A-rearranged acute leukemia. The partnership with Incyte for Niktimvo further strengthens its market presence in GVHD.

Comparison to Industry Standards

• The $7.7 million in net product revenue for Revuforj in its first five weeks is a strong start compared to other recent oncology drug launches.
• Companies like Jazz Pharmaceuticals with Vyxeos have shown the potential for significant revenue generation in the AML space.
• The $692.4 million in cash provides Syndax with a substantial financial runway compared to other similarly sized biopharmaceutical companies.
• Incyte's involvement in the co-development and co-commercialization of axatilimab provides a strong partnership model, similar to other successful collaborations in the industry, such as between Novartis and MorphoSys.

Stakeholder Impact

• Shareholders: The positive results and future outlook are likely to be viewed favorably by shareholders.
• Employees: The company's growth and commercial success can boost employee morale and job security.
• Patients: The availability of new therapies like Revuforj and Niktimvo provides additional treatment options for patients with leukemia and GVHD.
• Suppliers: Increased sales and clinical trial activity can lead to higher demand for suppliers of research and manufacturing materials.
• Creditors: The company's strong financial position reduces credit risk for lenders.

Next Steps

• Submit a supplemental NDA filing for revumenib in R/R mNPM1 AML in the second quarter of 2025.
• Initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy in the first quarter of 2025.
• Initiate multiple trials of revumenib in combination with standard of care regimens in newly diagnosed acute leukemia patients who are fit to receive intensive chemotherapy, starting in the second half of 2025.
• Complete enrollment in the MAXPIRe trial of axatilimab in patients with idiopathic pulmonary fibrosis (IPF) in 2025.
• Report Phase 1 data from the trial evaluating the combination of revumenib with intensive chemotherapy (7+3) followed by revumenib maintenance treatment in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients in the second half of 2025.

Key Dates